Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.
The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients. Study patients received valsartan 80mg bid for 1-2 weeks followed by the experimental drug LCZ696 100mg bid for 2-4 weeks. The primary objective of the study was to compare LCZ696 to valsartan in in reducing the rate of cardiovascular death and total hospitalisations in heart failure patients with preserved ejection fraction.
There are approximately 13 million heart failure patients worldwide, half of which are believed to suffer from HFpEF. As of today, there is no approved treatment for such patients. The PARAGON-HF trial was undertaken to determine whether sacubitril/valsartan could have a positive impact on the treatment of HFpEF, similar to its impact on heart failure patients with reduced ejection fraction (HFrEF). Sacubitril/valsartan is considered to be the first-choice treatment in heart failure HFrEF.
Based on the topline results that have been announced, findings from the trial suggest that treatment with sacubitril/valsartan may result in clinically important benefits in HFpEF. However, we will have to wait and see the detailed results when they are presented at ESC 2019. The researchers will also discuss potential next steps with clinical experts and regulators at that time.
HealthManagement.org will be there at the ESC Congress 2019 and will report complete findings from the PARAGON-HF trial once they are presented.
Latest Articles
HFPEF, heart failure, ESC Congress 2019, #ESC2019, PARAGON-HF, preserved ejection fraction
Topline results of the PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF); complete findings will be presented at the ESC Congress 2019 in September.
